ArticleData in brief2025
Data on the docking of millet-derived secondary metabolites as multi-target ligands for diabetes.
Article in Data in brief, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the therapeutic mechanism ofFrontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The deterioration of human health due to unhealthy lifestyle and dietary habits has led to a worldwide increase in various metabolic diseases that significantly affect public health. Diabetes is one of the most serious health problems, is caused by abnormal metabolic processes and is becoming increasingly common. According to World Health Organisation (WHO) reports, a significant proportion of the world's population suffers from these diseases and their incidence continues to rise at an alarming rate. These metabolic disorders are characterised by elevated blood sugar levels, which serve as a warning sign for a variety of other health problems. Factors contributing to these diseases include a high-fat diet, insufficient physical activity, genetic predisposition, lack of exercise and underlying diseases. Diabetes mellitus, a fast-growing chronic metabolic disease, is characterised by insufficient insulin production by the pancreas or the body's inability to use insulin action. Various strategies are recommended by health and nutrition experts to manage this condition, including lifestyle changes, exercise, low-carbohydrate and low-fat diets and intermittent fasting. In cases where these measures prove insufficient, medication may be prescribed. However, the development of multi-drug therapies for metabolic disorders has proven to be an attractive field for pharmacists as they address several diseases simultaneously. Despite the promising effects of multi-drug therapies, the high costs and potential side effects associated with recently developed drugs necessitate alternative approaches. The utilisation of natural bioactive compounds from plant extracts represents a promising high-throughput strategy. This approach utilises network pharmacology and screening methods to identify potential ligands that act as inhibitors for the treatment of complex, interconnected diseases. In the current investigation, we used a molecular docking approach to investigate secondary metabolites from millet as potential multi-target ligands for the treatment of diabetes and obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.